Abaloparatide
1 NDC across 1 manufacturer|0 Generic,1 Brand
Abaloparatide is used to treat postmenopausal osteoporosis, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Apr 28, 2017. In 2024, Medicare Part D spent $258 million on Abaloparatide across 89,000 claims for 17,000 beneficiaries.
Abaloparatide is available as 1 NDC from 1 manufacturer (0 generic, 1 brand), with NADAC prices from $1745.14 to $1745.14 per ML. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
1
0G / 1B
Manufacturers
1
competing in market
Price Spread
$1745.14 – $1745.14
per ML
7d Activity
avg +0.0% WoW · of 1 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
1 manufacturer producing ABALOPARATIDE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
TYMLOS 80 MCG DOSE PEN INJECTR | $1745.1403 per ML | — |
Frequently Asked Questions
What is Abaloparatide used to treat?
Abaloparatide is used to treat postmenopausal osteoporosis, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Abaloparatide?
In 2024, Medicare Part D spent $258 million on Abaloparatide across 89,000 claims for 17,000 beneficiaries.
How many Abaloparatide products are on the market?
The Abaloparatide drug market contains 1 NDC from 1 manufacturer — 0 generic and 1 brand product.
What is the price range for Abaloparatide?
NADAC reference prices for Abaloparatide range from $1745.1403 to $1745.1403 per ML.
Which manufacturers make Abaloparatide?
1 manufacturer lists Abaloparatide in NADAC. Ranked by number of NDCs, the largest are Radius Health, Inc. (1).